The Barcelona neurotechnology enrolled ten patients and implanted eight during brain tumour resection at Salford Royal Hospital, completing the first human cohort for any graphene-based neural interface. Full results due later in 2026.
A KU Leuven team led by Peter Janssen trained three rhesus macaques to pilot avatars through virtual environments using implanted multi-array BCIs, with premotor cortex outperforming primary motor cortex and a single fixed decoder generalising across perspectives, avatars, and dynamic targets.
A Mark Hersam-led team at Northwestern has demonstrated aerosol-jet-printed neuromorphic devices that generate biologically realistic voltage spikes and trigger responses in mouse cerebellum slices, a first for printed electronics and a potential route to lower-cost, flexible neural interfaces.
The Eindhoven-listed neurotech priced a private placement at €3.00 per share, led by EQT Life Sciences, to expand ARC-EX commercial operations and advance ARC-IM through regulatory work. Cash runway extends into Q1 2028.
The ExaStim system — a transcutaneous spinal cord stimulator for people with chronic spinal cord injury — has received FDA 510(k) clearance, making it the first device of its kind cleared for both clinical and home use in the United States.
A UC Irvine-led team has demonstrated the first brain-computer interface that simultaneously controls a walking exoskeleton through decoded brain signals and feeds artificial leg sensation back to the user's sensory cortex — closing the loop on locomotion for the first time.
California startup Sabi has exited stealth with a non-invasive EEG beanie packing up to 100,000 miniature sensors, a brain foundation model trained on 100,000 hours of neural data, and a plan to ship a consumer thought-to-text device by the end of 2026. Khosla Ventures leads.
The International Neuroethics Society convenes across Stanford, Lucca and Stellenbosch as the BCI sector absorbs $960 million in Q1, a Chinese reimbursement benchmark of US$900 per implant, and 20 Neuralink patients — and the governance window is narrowing.
The Melbourne-based startup has received FDA approval to begin a first-in-human study of Phantom X, an implanted sensor array that reads neuromuscular signals from a residual limb without entering the nervous system — aiming to give amputees more natural prosthetic control.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.